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Simple Summary: This paper explores the ways in which biomedical research that
uses nonhuman animal subjects generates financial profits and gains for humans who are
associated with the industry. Research establishments, scientists, regulators and persons that
inspect laboratories for compliance, those associated with granting licences, companies that
sell nonhuman animal subjects and that supply equipment for the research, and corporations
that market the resulting products are among those that benefit financially. These profits are
rarely discussed—they seem to be camouflaged by the focus of the moral convention that
assumes that human health-related needs prevail over those of the nonhuman animals who
are so used. The paper concludes by calling for an end to the denigration of nonhuman
animals as experimental subjects who can be used as commodities for profit-maximisation
and as tools in experiments for human health benefits.
Abstract: Each year millions of nonhuman animals suffer in biomedical experiments
for human health benefits. Clinical ethics demand that nonhuman animals are used in
the development of pharmaceuticals and vaccines. Nonhuman animals are also used for
fundamental biomedical research. Biomedical research that uses nonhuman animals is
big business but the financial gains are generally occluded. This paper explores how
such research generates profits and gains for those associated with the industry. Research
establishments, scientists, laboratories, companies that sell nonhuman animal subjects, that
supply equipment for the research, and corporations that market the resulting products
are among those that benefit financially. Given the complex articulation of ethical codes,
enormous corporate profits that are secured and personal returns that are made, the accepted
moral legitimacy of such experiments is compromised. In order to address this, within
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the confines of the moral orthodoxy, more could to be done to ensure transparency and
to extricate the vested financial interests from the human health benefits. But such a
determination would not address the fundamental issues that should be at the heart of
human actions in respect of the nonhuman animals who are used in experiments. The paper
concludes with such an address by calling for an end to the denigration of nonhuman animals
as experimental subjects who can be used as commodities for profit-maximisation and as
tools in experiments for human health benefits, and the implementation of a more inclusive
ethic that is informed by universal concern about the suffering of and compassion for all
oppressed beings.
Keywords: anthropocentric; biomedical; business; ethics; experiments; nonhuman
animals; profits
1. Introduction
The globally-prominent current neoliberal form of governance reduces everything and everyone to a
commodity [1]. David Harvey comments that neoliberalization “has meant, in short, the financialization
of everything” [2] (p. 3). Based in cutting public expenditure whilst increasing privatisation and
entrenching decentralisation, neoliberal economics have transformed the provision of services including
those associated with human health [3]. The increasing commodification of human health provision is
based in the “alleged virtues of the untrammelled market, business culture and entrepreneurship” [4]
(p. 24) and this market-based, profit-driven approach is central to all elements of human healthcare [5],
including that which involves the use of nonhuman animal subjects in biomedical research [5]. Utility,
profit and wealth undoubtedly influence choices made about nonhuman animal biomedical research [6]
because experimenting on nonhuman animals is big business [7]. For example, the research and
development of medicines for the pharmaceuticals industry is largely based in the use of nonhuman
animal subjects [8]. Reports suggest that testing a potential medicine can involve the use of up to 800
nonhuman animals at a financial cost of over US$6 million [9]. The nonhuman animals used and the
money spent are clearly thought to be worth it by the pharmaceuticals industry; worldwide the industry
is worth US$300 billion, with an anticipated rise to US$400 billion within three years [10]. In this paper
I centre on the profits that are made from the nonhuman animal subjects who are used in such research. I
do this in order to call into question the often purely ethical rationale that is invoked to justify the use of
nonhuman animals in biomedical research. I draw on Robert Garner’s [11] work on the moral orthodoxy
to explore the pretext for the use of nonhuman animal beings for human health benefits. Research that
uses nonhuman animals for experiments and testing is considered to be a moral issue in a number of
countries. For example, in the European Union (EU) the use of nonhuman animals for research and
testing of cosmetics is considered to be unwarranted and unethical and thus is illegal [12], whereas the
use of nonhuman animal subjects in biomedical research is considered to be warranted and ethical if
it conforms to the legal requirements [13]. The legal position, and associated moral orthodoxy, gives
primacy to human-health related medical science. This primacy is found, as well, in public attitudes.
There is more public acceptance of experiments that use nonhuman animal subjects if the experiments
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have human health objectives [14]. Because I challenge the ethics of the use of nonhuman animals in
biomedical science, which is given ethical primacy, I seek to confront the assumption about the ethical
legitimacy of the use of nonhuman animal experiments across the board.
In order to achieve my aims I begin with an exploration of the profit-led agenda that pervades the
human concern for human health. Clinical ethics demand that nonhuman animals are first in line
for much human-centred biomedical research and development, and in challenging the assumptions
contained in such ethical codes I explore how the annual use of millions of nonhuman animals
in biomedical research generates profits and gains for those associated with the nonhuman animal
experiment industry. These profits are rarely discussed—they seem to be camouflaged by the focus of
the moral convention that assumes that human health-related needs prevail over those of the nonhuman
animals who are so used. Gains and profits are generated for those associated with the nonhuman animal
biomedical research industry. Research establishments, scientists, technicians and other professionals
who work in laboratories, regulators and persons who inspect laboratories for compliance, those
associated with granting licences, companies from which nonhuman animal subjects are bought and
that supply the equipment for the research, and corporations that sell the resulting pharmaceuticals and
procedures are just some of those that benefit financially from the research. But required partiality to
human health benefits and the claim that biomedical experiments that use nonhuman animal subjects
are ethical because they conform to required clinical ethical codes and conventions conceal these
revenues. I conclude that even this anthropocentric form of ethics is compromised by the prominence of
profit-making for the industry and the gains that are made by researchers who use nonhuman animals in
biomedical experiments.
2. Human Health and the Neoliberal Agenda
In this current phase of modernity, which Zygmunt Bauman characterises as “a contraption attempting
to make life with fear liveable” [15] (p. 6), our fear of the unknown is eased by hope. In the case of
human illness our anxious lives are made more bearable by the hope that we can predict and control
a range of diseases and conditions. An inevitable consequence of the hyper-visibility of human health
risks is that we feel threatened by an increasing range of maladies [16] (p. 50) even though human
health has generally improved [17]. Our anxieties persist because we cannot eradicate the current array
of human diseases and, even if we could, human movement across the globe has led to the resurgence
of older infectious diseases and the development of newer ones [18] (p. 8). Furthermore, the spread
of new strains of contagious diseases [such as pandemic influenza and Ebola] has resulted in additional
worries about the development of conditions that might be resistant to known treatments [16]. Our
health anxieties are exacerbated by developments in genetic research, which enable predictions to be
made about our individual probability of developing specific genetic conditions [19]. Although this
“era of personal genomics” [20] means that predictive and precision medicine and treatments can be
used, such predictions can induce fear in those of us who are told that we hold the genetic markers
of a dreaded disease [21]. In this “age that is guided by science” [22] (p. 15) we hope that scientific
research and expert systems [23] (p. 115) will help us stave off feared and unwanted threats to our
health. This dependence on medicine is exacerbated by our fear of ageing and death, which have
become medicalised processes [24]. Atul Gawandi observes that “Lacking a coherent view of how
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people might live successfully all the way to their very end we have allowed our fates to be controlled by
the imperatives of medicine, technology, and strangers” [24] (p. 8). We have a great deal of confidence
in medicine [25] and undoubtedly human health has improved as a result of medical innovations. But
scientific breakthroughs have not given us unconstrained control over our health futures, though the
calculation of the probability of a health hazard occurring is “the next best thing to (alas unattainable)
certainty” [15] (p. 10).
Our concern about our health is evidenced by the amount we spend every year on human health care.
Health care is big business. For example, the USA is reported to have the highest health spending in
the world, in 2012 equivalent to nearly 18 percent of its Gross Domestic Product (GDP) [26]. In the
UK the corresponding figure was 9.6 percent of GDP [26]. Increased health spending is said to deliver
better services to humans who are in need of those services. In the UK, health provision is claimed to
be “continuously evolving with the aim to deliver improved services to patients” [27] (p. 11). But this
“continuously evolving” system comprises a mix of market and non-market sectors [27]. Like in the
USA [28] (p. 14), health care in the UK is characterised by “medical neoliberalism”, which is based
in individual responsibility for health and the notion that private providers in the market sector offer
medical services that are of higher quality than those provided by the non-market sector [29]. So, along
with welfare, education and social security, the focus of health care is on free markets and free trade [26]
(p. 14). Free market delivery mechanisms (which are the professed health care reforms we are familiar
with hearing about in the UK) centre in a for-profit system [29] (p. 83). This neoliberal for-profit health
care system means that a growing share of the global spending on health care, amounting to over US$5
trillion, is being shifted from the public to the private sector [30]. Elemental to this is the medicalisation
of an increasing range of human conditions, to which pharmaceutical companies respond by charging
high prices for an increasing range of drugs [31] (p. 24). But those who are least in a position to pay are
often those who are in most need of health care, for example the oldest and the youngest citizens, those
who live with chronic illness or disabilities, and those who are living in poverty [30]. Even in the wealthy
USA, high prices are making health care too expensive for many [32]. Dr. Pamela Hartzband and Dr.
Jerome Groopman lament, “Patients are no longer patients, but rather customers or consumers” [33]
(p. 102).
There is a lot of money to be made out of the customers and consumers of services and products for
human health and, where there is little money to be made pharmaceutical companies, for example, are
less likely to innovate [34]. The desire to maximise profits has been pointed out in current news media
reports about the Ebola virus. In Guinea, Liberia and Sierra Leone there have been a total of 26,044
“confirmed, probable and suspected cases” of Ebola and at least 10,808 people in those countries have
been killed by the virus [35]. In Europe there have been two reported cases (one in Spain and one in
the UK) and in the USA there have been four cases of Ebola, and one reported death [35]. At the time
of writing there is no vaccine against the virus [36]. Erica Etelson [37] suggests a reason for this. She
refers to Margaret Chan’s (Director of the World Health Organization) assertion that the pharmaceutical
industry’s failure to develop a vaccine up to now is because “A profit-driven industry does not invest in
products for markets that cannot pay” [37]. Etelson [37] infers that, had the Ebola virus been detected
in the USA sooner, a vaccine would already be available. She concludes that “Big Pharma’s greed
isn’t some kind of aberration; it’s an inherent feature of free-market capitalism: A capitalist system,
Animals 2015, 5 628
by design, puts profits over people” [37]. This emphasis encourages a perspective on “benefits” that is
oriented towards benefits as profits rather than on benefits as improvements to human health [31].
This is a disgrace, but it is not the only disgrace. This free-market health system ensures that the
human health industry not only redefines benefits as profits and promotes profits over human beings, it
makes profits from the use of nonhuman animals. These financial profits and gains are often occluded by
the focus on the human health benefits that are purported to make such experiments ethically justifiable.
3. Research Ethics and Biomedical Experiments
The sought after utopian future based in the human ability to prevail over our bodily limitations [38]
is based in a commodified, dystopian past, present and likely future of misery and suffering for millions
of nonhuman animals who are used in biomedical experiments [16]. However, this cost to nonhuman
animals is considered to be warranted if the human health benefits that ensue are important enough to
justify the suffering caused [11]. P. Michael Conn and James V. Parker argue that “virtually every major
medical advance of the last century is due, in part, to research with animals” [39] (p. 158). The human
health benefits are summarised by Professor Robert Winston on the UK-based Understanding Animal
Research (UAR) alliance website [40]. He states that, “Animal research has advanced the treatment
of infections, helped with immunisation, improved cancer treatment and has had a major impact on
managing heart disease, brain disorders, arthritis and transplantation” [40]. In addition, UAR announces
a range of future human health possibilities that could result from such experiments, such as the treatment
of chronic diseases [41]. Although there is no legal requirement for nonhuman animals to be used for
fundamental biomedical research there is a legal requirement for nonhuman animal subjects to be used in
the development and testing of medicinal drugs and vaccines [42] which, the Association of the British
Pharmaceutical Industry among others declares, is “to ensure patient safety” [43]. This form of human
protection was defined in the Nuremberg Code.
The Nuremberg Code, which has served as a foundation for ethics in clinical research, comprises
a series of research ethics principles for human experimentation that were drafted at the end of the
Doctor’s trial in Germany in 1947 [44]. It is in Item 3 of the code that reference is made to nonhuman
animals. This item states that an experiment that uses humans “should be so designed and based on
the results of animal experimentation and a knowledge of the natural history of the disease or other
problem under study, that the anticipated results will justify the performance of the experiment” [45].
Further protocols have followed, such as the Helsinki Declaration, which reinforce the requirement that
nonhuman animal experiments should precede human experiments [46]. This requirement is repeated in
national and international laws, codes, and declarations. Such protocols are designed to protect against
human experimentation atrocities like the Tuskegee Syphilis Study, Human Radiation Experiments in
America, Nazi Experiments in Germany, and the compulsory sterilization programme in India [47].
But such atrocities continued and persist. For example, the Tuskegee Syphilis Study continued until
1972 and, in terms of current practices, Mohammed Imran and colleagues observe that “Still unethical
studies are found in developing countries. Studies such as experimental anticancer drugs in 24 cancer
patients without adequate prior animal testing and informed consent in Kerala” [47] (p. 203). The
lack of informed consent is shameful, dangerous, and unethical. Leaving aside, for a moment, the
ethical issues associated with using nonhuman animal subjects in such experiments, there is no consensus
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about the adequacy of protection that is offered to humans by the prior testing of drugs on nonhuman
animal subjects.
The claims that biomedical experiments that use nonhuman animals protect humans are contentious.
Although a 2011 poll of nearly 1000 biomedical scientists undertaken by Daniel Cressey (for the journal
Nature) found that more than 90 percent “agreed that the use of animals in research is essential” [48],
alternative scientific opinions identify problems, and indeed risks, associated with the prediction of
human health outcomes on the basis of nonhuman animal experiments [49]. Probably the most obvious
example is that of the drug Thalidomide, which was first prescribed to pregnant women in the 1950s
to alleviate nausea. The drug led to devastating foetal effects in humans. After it was withdrawn tests
in pregnant mice, rats, and guinea pigs led to no negative foetal effects, though testing in New Zealand
white rabbits led to similar devastating foetal effects as found in humans [50] (p. 125). Another reported
problem lies in the effective treatments for humans that would not be available if nonhuman animal tests
were relied upon [7]. For example, some cancer drugs that are used as effective treatments for human
cancers were ineffective in treating cancer in mice [7] (p. 17). Concerns have also been raised about the
scientific rigour of some experiments. For example, Pandora Pound and her colleagues argue that many
studies that use nonhuman animals are of “poor methodological quality” [51] (p. 517) which means that
the research is “wasted because it is poorly conducted and not evaluated through systematic reviews” [51]
(p. 514). Ray Greek and colleagues conclude that “the requirements for animal testing found in the
Nuremberg Code were based on scientifically outdated principles, compromised by people with a vested
interest in animal experimentation, serve no useful function, increase the cost of drug development, and
prevent otherwise safe and efficacious drugs and therapies from being implemented” [52] (p. 1). As we
have seen, Michael Conn and Parker disagree [39] (p. 158). This is a vital difference of scientific opinion
but the fundamental issue is not the efficacy of the use of nonhuman animal subjects in biomedical
experiments it is the ethical legitimacy of nonhuman animal experimentation [5].
The assertion that prior testing on nonhuman animals has ethical legitimacy is doubted by many,
including doctors [53] and patients [54]. For example, a study in Sweden [54] suggests that although
many researchers support nonhuman animal biomedical research broader support for such research is
not shared to an equal degree with human patients, who are the intended end-users and beneficiaries
of such research. This leads the authors, Malin Masterton and colleagues, to advise that “The moral
basis for using animals in research needs to be further discussed by all stakeholders” [54] (p. 24). The
overlooked stakeholders, the nonhuman animals who are used in biomedical research, do not have a
voice. We cannot deny that Jacques Derrida is right; nonhuman animals do suffer [55] (p. 28) and
ethical consideration of their suffering should have no prior limits or constraints [56]. In what remains
of this paper I offer a challenge to the anthropocentric ethics that permits nonhuman animal experiments
to take place by bringing to light the profits and gains made by those who are associated with the industry,
profits that are camouflaged by the position that human-health needs prevail over the wellbeing of the
nonhuman animal subjects who are so used. Ultimately I challenge the ethical legitimacy of the use of
nonhuman animal subjects in biomedical research.
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4. Nonhuman Animals, Ethics and Biomedical Experiments
A conservative estimate puts the number of living vertebrate nonhuman animals who are used
annually in experiments worldwide at 115.3 million [57] (p. 327). The majority of countries (79%)
do not publish statistics so it is difficult to obtain accurate data [57] (p. 327). For example the
People’s Republic of China, Egypt, Iran, India, and Thailand do not provide statistics about the number
of nonhuman animals they use. However, on the evidence available Katy Taylor and her colleagues
estimate that the United States, Japan, China, Australia, France, Canada, United Kingdom, Germany,
Taiwan and Brazil use the highest numbers [57] (p. 327). The figures for most countries cover mainly
vertebrate nonhuman animals (who are considered to feel pain); there are many more invertebrates [58]
(and some vertebrates) who are not included in the statistics as they are not considered to be “animals”
for purposes of “protection” [59]. For example, according to the USA Department of Agriculture,
Animal and Plant Health Inspection Service, in the Fiscal Year 2010 over 1.13 million nonhuman
animals were used in experiments in the USA [60] but the USA Federal Animal Welfare Act excludes
“cold-blooded” nonhuman animals and rats, mice, birds, reptiles, amphibians, and nonhuman animals
used in agricultural experiments. Rats and mice comprise the overwhelming majority of all laboratory
subjects used [61]. The figure of 11.5 million nonhuman animals who were used in experiments in
the European Union (EU) in 2011 [62], does include mice and rats but, with the exception of some
cephalopods, does not include invertebrate species. As in many other countries the EU statistics
also exclude “the maintenance of breeding genetically modified . . . animals, animals killed solely to
provide tissue, “surplus” conventional animals bred but then killed, and animals exploited in behavioural
research, including the marking of “wild” fish” [63]. In 2013 over four million of the stated total number
of nonhuman animal subjects used in the EU were used in experiments in the UK (4,017,758 nonhuman
animals used in 4,121,582 experiments) an increase of 0.3 percent (+11,600 procedures) on the previous
year [64]. Again most invertebrate species were excluded from this figure. The UAR acknowledges that
for the UK “The number of animals used in research has risen in recent years” but, the organisation
suggests, “This is for a variety of reasons, not least because more research is being carried out to
understand, prevent and treat human and animal diseases, and to protect the environment” [65]. Although
statistical data provide a measure of the quantitative scale of the pain and suffering caused, such data do
not call attention to the experiences of suffering of individuals [66] and thus can serve to distance us from
understanding the lived experiences of individual nonhuman animal subjects who are used in biomedical
research [67]. Individual nonhuman animals are subjected to “procedures against their own individual
interests, including those that involve the deliberate infliction of suffering, harm, and/or death” [63].
Nonhuman animal subjects are used in both biomedical and non-biomedical research.
Non-biomedical research includes experiments to determine the effects and safety of a range of products,
processes, and events such as those associated with warfare, accidental damage, food processing
and cosmetic enhancements [57]. The distinction “biomedical” and “non-biomedical” is important,
notwithstanding how ambiguous it might be, in terms of industry justifications and public views about
the veracity of nonhuman animal experiments. Regarding public support, it is usually reported that
there is less support for research that uses nonhuman animals if the research is not seen as necessary for
human health benefits. For example, a 2012 Ipsos/Mori poll in the UK revealed that 66 percent of those
who conditionally support experiments that use nonhuman animals only do so if the experiments are for
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medical research purposes “where there is no alternative” [68] (p. 7). This is because (at least some)
nonhuman animals are considered to have moral standing [11].
A being has moral standing if she or he can be morally wronged [69]. Possession of moral standing
means that the being concerned should be given moral consideration. There is considerable discussion
about the source of moral standing [69] and the foundations are complex and nuanced. It is not possible
to do justice to the discussion here. However what is clear, fundamentally, is that all humans have moral
standing and have equal moral standing, which means that often we hear what Richard J. Arneson refers
to as “platitudinous statements” [70] (p. 103) that humans should not be subjected to discrimination.
Platitudinous because, despite there being equal moral standing among all humans, many humans and
groups of humans are subjected to discrimination. In contrast, for nonhuman animals discrimination
is permitted and required, even where their moral standing is recognised. A continuum of recognition
of the moral standing of nonhuman animals which draws out the differences has been developed by
Garner [11]. At one end of this continuum is the idea that nonhuman animals have no moral standing
because, for example, they are deemed to lack sentiency. In the centre of the continuum is the current
moral orthodoxy, which summarizes the existing UK position on the moral standing of “protected”
nonhuman animals. Garner explains that under the terms of the “moral orthodoxy” it is expected that
the interest that nonhuman animals have in not suffering can be overridden for what is considered to the
greater good of humans [11] (p. 15). At the other end of the continuum there are challenges to both
the granting of no moral standing to nonhuman animals and to the moral orthodoxy because at this end
nonhuman animals are granted moral equality with humans [11] (p. 18).
The current moral orthodoxy is entrenched in biomedical research as “it is widely held that partiality
to human interests is not only defensible, but obligatory” [71] (p. 245). Although many biomedical
researchers seek to fulfil the moral imperative of the 3Rs (replacement, reduction, and refinement)
and aspire to eliminate the use of nonhuman animal subjects [57], harm to nonhuman animal subjects
in laboratories “is counted as a small thing in comparison with the research work undertaken” [63]
(p. 67). The required partiality to human interests is based in the widely held view that nonhuman
animals have some moral status but that humans are morally superior. This serves to support the
claim that biomedical research that uses nonhuman animal subjects and which conforms to the legal
requirements is unquestionably ethical. But much of the research that goes on in the biomedical sphere
is morally illegitimate even within the limitations of the moral orthodoxy [11]. The moral legitimacy is
compromised by the profit-making nonhuman animal experiment industry and the gains that are made
by researchers who use nonhuman animals in biomedical research.
5. Research Funding
Biomedical research is funded by governments, private companies and organisations, and by
donations from individuals and charities. In the UK, biomedical research receives millions of pounds of
government funding. For example, in 2012 the UK Government announced “the Biomedical Catalyst
. . . .an integrated £180m funding programme to support the development of innovative solutions to
healthcare challenges by both SMEs (Small and Medium-Sized Enterprises) and academics across the
UK” [72] (p. 15). Private awards and grants augment the amount that is available for such research. In
the UK the biggest investor is the pharmaceutical industry, which spends £12 million a day on such work,
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representing 70 percent of the total funds [73] (p. 5). Much of this money is directed to experiments
that use nonhuman animal subjects. Charitable donations make additional and significant contributions
to the funding of such experiments. Out of a total income of £214 million for 2009/10 the British Heart
Foundation allocated £48.4 million to the funding of research that involved nonhuman animals [74]. In
the same year the UK Alzheimer’s Society assigned £700,000 of its annual income of £58.7million to
such work and in 2010 Parkinson’s UK apportioned £8 million of its total income of £21million [74].
A spokesperson for the charity Cancer Research UK commented that “We have strict ethical policies
in relation to animals and follow rigorous government guidelines to ensure that animals are only used
where there’s no alternative” [74]. Cancer Research UK allocated £334 million of its annual 2009/10
income of £446 million [74]—that is nearly twice as much as the UK government set aside in 2012 for
its “Biomedical Catalyst” [72] (p. 15).
The costs of biomedical research and development are escalating [75]. Much of the money
available is used to fund a range of organisations that undertake nonhuman animal based biomedical
research. A great deal of such research is carried out in universities. Universities in the UK are
part of an “academic political economy” that is characterized by decreasing government funding so
“the application of corporate business practice in universities has been widespread, to ensure their
survival” [76] (p. 293). Although 24 of the 64 projects that are receiving funds from the “Biomedical
Catalyst” are university-led [72] (p. 15), funding from private organisations outstrips that secured
from government sources so gaining external funding, (such as from the pharmaceutical industry
and charitable donations) is crucial. Principal biomedical research universities in the UK, such as
Edinburgh, Oxford and Cambridge, devote vast sums of money to research that uses nonhuman
animal experiments [77]. There is a greater sum of federal funding in the USA. According to the
People for the Ethical Treatment of Animals (PETA) [78] the USA National Institute of Health (NIH)
allocates 40 percent of its annual research budget to research that uses nonhuman animal subjects.
Using this figure they calculate that NIH spent more than $16 billion on such experiments in 2010
alone [78]. Substantial annual increases in health-related research and development funds are demanded
by biomedical researchers who argue that such increases are “essential to maintaining our momentum of
progress in the battle against disease” [75]. Similar demands are being made in the UK and across the
world. But the “battle against disease” is not the only awaited feature of the gaining of such funds.
Biomedical researchers in academia rely on grants to fund their research not only to fund research but
because securing a research grant enhances individual academic reputations and enhances the reputation
of the university at which they are employed [76]. Gaining research funding is a core component of
evaluations for promotion [79]. Jean Swingle Greek and Ray Greek argue that “Conducting animal
experiments is a convenient and highly effective way for these researchers to gain career prestige and
job security, and for the universities who employ them to obtain lucrative research grants. There is a
quid pro quo relationship between research institutions and those giving the grants” [7] (p. 25). In
biomedical research the paradigm of nonhuman animal experiments is the accepted pattern for research
and “Once a pattern of animal experimentation becomes the accepted mode of research in a particular
field”, Peter Singer notes “The process is self-reinforcing and difficult to break.” [80] (pp. 90–91).
There is more money available for research and development that involves the use of nonhuman animal
subjects than for research that explores alternatives. The search for alternatives is often based in the
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3Rs, first advanced by W. M. S. Russell and R. L. Burch in 1959 [63] (p. 43). Although the UK
government makes funds available for work on alternatives [81] (p. 27) it stresses that it “recognises
that the carefully regulated use of animals plays an essential role in scientific research, particularly in
ensuring new medicines are safe and effective” [72] (p. 40). Humane Society International states that
“For 2011/2012, the government gave just £5.46 million to the National Centre for the Replacement,
Refinement and Reduction of Animals in Research, with roughly one-third spent on research to replace
animals. This is compared to an overall annual UK science budget of £4.6 billion” [82]. Consequently,
individuals and corporate bodies who “have career advancement, prestige, and the bottom line to look
after, protect the animal experimentation industry under the guise of protecting human health” [7] (p. 24).
6. The Business “Animal Model”
The UK pharmaceutical industry alone invests vast sums of money in research and development.
Across the EU in 2010 the pharmaceutical industry invested C27 billion in these activities [73] (p. 5).
The UK pharmaceutical industry reports that 37 percent of current sales return is spent on research
and development [73] (p. 5). When we recall that the UK industry spends £27 million daily on such
work (see above) we gain an insight into the scale of their total sales return. An indication of the
profits made from pharmaceuticals can be gleaned from individual company returns. For example,
the UK-based pharmaceuticals company GlaxoSmithKline reported a pre-tax profit of £548 million for
the three months to the end of September 2014 which, although considerably down from the figure of
£1.4 billion for the same period in 2013, was reported to be better than expected [83]. Shareholders
benefitted as “shares rose 4% after its third-quarter results beat expectations and it pledged to return an
additional £4bn to shareholders via a special share scheme” [83]. Much of the research and development
undertaken by GlaxoSmithKline involves experiments that use nonhuman animal subjects. Although
the company does not provide the statistics it is evident that nonhuman animals subjects are used as it
reports that the number used in 2013 was down by 10% on that for 2012 [84]. Additionally, the company
argues that “Animal testing is not the cheap option—our animals are fed, housed and looked after by
qualified professionals throughout their lives. A veterinarian is also on site or on call 24 h a day, seven
days a week” [84]. In the UK, veterinary practitioners and Named Animal Care and Welfare Officers
(NACWOs) are employed in laboratories where nonhuman animal subjects are used in experiments [67].
Their role is to recognise and monitor the suffering of nonhuman animals in the laboratory with a view
to improving their welfare [85]. This brings me to the money that can be made by those who sustain the
use of nonhuman animals in biomedical experiments.
With at least 115.3 million nonhuman subjects used in experiments across the world every year
there is a great deal of money to be made out of the breeding and selling of nonhuman animals to
laboratories. Charles River is one of the suppliers of nonhuman animals to the global industry. The
list of nonhuman animals the company supplies is extensive. Mice and rats are used in vast numbers
in biomedical experiments, not least because they are thought to react to medication in similar ways to
humans [86] and because they are relatively inexpensive to buy [87]. A three week old Swiss pigmented
mouse, who is marketed as being “for general purpose”, is sold by Charles River for US$10.10 [if he is
male] and for US$10.95 (if she is female) [88]. The “genetically engineered” mouse who is sold under
the label 11BHSD2 is bred in the USA and is promoted by Charles River as being “Ideal for cardiac
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hypertrophy, heart failure” [88]. Depending on “types” and age an individual mouse costs between $32
and $181, with additional charges of $10 for each additional week of age [88]. In 2013 the company’s
total revenue was US$1.17 billion [89]. Rats and mice who are bred for use in the laboratory have been
subjected to decades of selective breeding [90] (p. 22), and the genetic “engineering” of nonhuman
animals to match the needs of researchers who focus on specific conditions is now mainstream. When
such genetically modified nonhuman animals were developed and began to be sold as commodities on
the market substantial profits were made by the humans and businesses involved. Huge profits continue
to be made. The most familiar example is OncoMouser, a transgenic mouse who was developed in
1984 by Harvard to have a predisposition to cancer. The comprehensive commodification of the mice is
evidenced by the news that OncoMouser was named “Product of the Year” in 1988 by Fortune [91]. Not
a mouse, a “product”. A great deal of money continues to be made out of the mice. Du Pont, the company
that subsequently owned the patent for these living beings, imposed “hefty fees and restrictions” on the
use of OncoMouser [92]. The patent for OncoMouser remains in dispute. Douglas Hanahan and
colleagues argue that “Such use of technology patents as end products to generate revenue, rather than as
means to develop products, is a socially controversial if not uncommon business practice that is applied
to research tools in biology and medicine” [92] (p. 2268).
Laboratories that use nonhuman animal subjects as experimental tools need to buy a range of
equipment to facilitate the experiments and to attend to the welfare of the nonhuman animals involved.
As we have seen, GlaxoSmithKline remarks on the heavy financial costs of the additional resources that
are required for its nonhuman animal biomedical experimentation programme. GlaxoSmithKline makes
vast profits while at the same time providing paid employment for related employees and enabling
profits to be made by companies that supply them with the nonhuman animals and the equipment
they use. Paradoxically, policies aimed at improving the welfare of nonhuman animals who are used
in laboratories have the potential for increasing the profits of suppliers as laboratory equipment must
conform to statutory requirements [5]. The equipment that is used in such research includes that which
is associated with housing, feeding, experimenting on and the killing of nonhuman animal subjects, The
catalogues of suppliers include advertisements for cages, restraints and guillotines. The Canada-based
company Lomir Biomedical is a supplier of a range of equipment for such research. The company
markets a variety of products and strives to invent new ones that can be marketed as responding to the
changing needs of biomedical scientists. For example, the company states that it has “identified a need
for a range of undershirts for laboratory animals as scientific procedures become much more refined.
Undershirts are an effective means of securing electrodes, connectors, Fentanyl patches or any piece that
needs to be kept in contact with skin.” [93]. One dog undershirt costs either US$50.99 or US$54.11,
depending on how many are ordered [93]. The company has an annual revenue of US$4,695,040 [94].
The multi-million dollar industry in nonhuman animal experiments is thriving [7]. Those who
supply nonhuman animals to research laboratories, along with the apparatus needed to house, feed,
and experiment on nonhuman animal subjects have a vested interest in sustaining the nonhuman animal
experiment paradigm [7]. The profits compromise the moral legitimacy of nonhuman animal biomedical
experiments even with the limited gaze of the moral orthodoxy.
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7. Conclusions
In this paper I have sought to examine the ways in which biomedical research that uses nonhuman
animal subjects generates financial profits and gains for humans who are associated with the industry.
My aims have been to make evident the often occluded economic benefits that are associated with
such research and, ultimately, to challenge the moral orthodoxy that permits nonhuman animal
experimentation to take place at all. The moral orthodoxy requires that biomedical experiments that use
protected nonhuman animals should conform to a cost-benefit analysis, where the benefits to humans
are deemed to be important enough to justify the costs (that is the suffering) to the nonhuman animal
subjects who are so used [11]. The human benefits that are considered to be important enough mainly
are associated with the advancement of knowledge and the development or toxicity testing of clinical
interventions [63]. Even in the current neoliberalised medical system that encourages a perspective on
“benefits” that is oriented towards benefits as profits rather than on benefits as improvements to human
health [31] the moral orthodoxy is not satisfied as the production of economic benefits is not important
enough for nonhuman animal suffering to take place under its terms.
The established paradigm on nonhuman animal biomedical experiments is based in the argument
that nonhuman animal experiments have utility because they have led to progress in the treatment of
human illnesses and offer safeguards in terms of patient safety. The moral orthodoxy is fulfilled by the
established paradigm if the legal requirements are adhered to and are satisfied. From this perspective the
financial benefits that accrue, and indeed the money that is spent in the first place, are side issues as the
main consequences of nonhuman animal biomedical experiments are the benefits to humans that ensue
by means of the development of new medicines or vaccines, improved diagnosis or better methods of
toxicity testing [8]. However, there is no consensus about this as there are those who argue that human
health does not benefit as humans are harmed by nonhuman animal biomedical experiments because
they cannot predict responses in humans [63]. From this perspective the money is not well-spent as
vested interest groups profit financially at the expense of human patients and thus the benefits are not
health-related, rather the benefits come in the form of the profits gained [7].
So, there is considerable doubt that some of what happens in the biomedical sphere is morally
legitimate even within the limitations of the moral orthodoxy [11]. Given the differences in opinion
about the efficacy of nonhuman animal experimentation and the complex articulation of ethical codes,
enormous corporate profits that are secured and personal returns that are made, the moral orthodoxy
is compromised. In order to address this, within the confines of the moral orthodoxy more could to
be done to extricate the vested financial interests from the human health benefits. The focus could
be on obligatory transparency and accuracy of numbers of nonhuman animals used, with a calculation
that includes all nonhuman animals who are used and who are squandered, a scrupulous analysis of the
effectiveness of nonhuman animal experiments and an openness about the financial profits that are made.
These determinations would make evident the efficacy, or not, of the use of nonhuman animal subjects
in biomedical experiments in tandem with the often occluded economic benefits that are associated with
such research. Given that nonhuman biomedical experiments are given ethical primacy within the narrow
scope of the moral orthodoxy, without such determinations the moral legitimacy of the use of nonhuman
animal subjects in all experiments will continue to be questioned. However, these determinations remain
restricted by an anthropocentric standpoint. They would not address the costs to the nonhuman animal
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subjects who are used in biomedical experiments because these costs would continue to be permitted
within the limitations of this anthropocentric moral orthodoxy.
I want to close with a challenge to the moral orthodoxy, a challenge that seeks to address the
fundamental issues that should be at the heart of human actions in respect of the nonhuman animals
who are used in experiments [67]. Such a challenge does not focus on the efficacy of experiments
or on transparency about numbers used and profits made, rather it centres on the implementation of
a more inclusive ethic that is informed by universal concern about the suffering of and compassion
for all oppressed beings [95]. This would affect a fundamental shift in the way we view nonhuman
animals, away from an anthropocentric approach to a way of looking at the world from the standpoint
of nonhuman animals with the goal of ending the denigration of nonhuman animals as experimental
subjects who can be used as commodities for profit-maximisation and as tools in experiments for human
health benefits. At the time of writing a petition (signed by 1.2 million people) has forced Ministers of
the European Parliament to debate a ban on nonhuman animal experimentation [96]. With the stated aim
of protecting humans and nonhuman animals, the petition demands legislation that will see the abolition
of “animal experimentation and instead makes compulsory the use—in biomedical and toxicological
research—of data directly relevant for the human species” [97]. Such a shift in legislation, and in the
allocation of funds, would affect moral progress by advancing the wellbeing of nonhuman animals,
well-being that is based in freedom from human-induced pain and suffering.
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